Nurtec (rimegepant) becomes first migraine therapy for acute and preventive treatment Additive benefits of anti-CGRP therapy and botulinum toxin in chronic migraine Safety of anti-CGRP therapy during COVID-19 pandemic Retrospective analysis supports erenumab in trigeminal neuralgia Long term data support eptinezumab safety and improved quality of life for patients Aimovig (erenumab) available on NHS in England and Wales Discovery of CGRP role in migraine recognised in Brain Prize 2021 New insights on structure and dynamics of CGRP receptor

CGRP in cluster headache

22 January 2020 | Videos

In the third in his series of videos about the future of CGRP therapies, Peter Goadsby describes the research that led to the approval of galcanezumab for the treatment of episodic cluster headache and looks forward to better understanding of how treatment can be optimised for patients most likely to benefit.

Educational Partners and Supporters (others pending) Amgen

Amgen

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2021 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |